Neonatal Hypoxic Ischemic Encephalopathy Clinical Trial
— BBASLOfficial title:
Prognostic Value of Arterial Spin Labeling Brain Perfusion MRI in Term Neonates With Hypoxic-ischemic Encephalopathy
Verified date | April 2023 |
Source | University Hospital, Bordeaux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose of this study will be to evaluate the prognostic value at 3 months of life of brain perfusion MRI determined by Arterial Spin Labeling technique in the first week of life of term newborns with hypoxic-ischemic encephalopathy requiring management in neonatal intensive care unit.
Status | Completed |
Enrollment | 31 |
Est. completion date | January 12, 2023 |
Est. primary completion date | January 12, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day to 8 Days |
Eligibility | Inclusion Criteria: - neonates with a term = 36 weeks of amenorrhea and birth weight = 1800 g. - presenting with perinatal asphyxia defined as combination of: - an acute perinatal event (such as placental abruption, cord prolapse, and/or severe foetal heart rate abnormalities); - and at least one of the following criteria: - Apgar score = 5 at 10 minutes of life, - mask ventilation or intubation at 10 minutes of life, - metabolic acidosis defined as pH < 7 or base deficit = 16 mmol/L or lactates = 11 mmol/L within the first 60 minutes of life on cord or other arterial venous or capillary blood sample. - patient treated or not with therapeutic hypothermia for 72 hours. - affiliated patient or beneficiary of a social security scheme. - informed and signed parental consent. Exclusion Criteria: - perinatal arterial ischemic stroke. - congenital neuro-metabolic disorder. - severe malformative abnormalities. - MRI contra-indication. - Poor understanding of the holders of parental authority |
Country | Name | City | State |
---|---|---|---|
France | CHU Bordeaux | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical outcome | judged as favorable, or as adverse in case of death or cerebral palsy | 3 months of life (Month 3) | |
Secondary | Clinical outcome | judged as favorable or as adverse | Month 6, Month 12 | |
Secondary | Prognostic performances of ASL | Prognostic performances of ASL in comparison with routinely used MRI parameters | Baseline | |
Secondary | Quality of ASL sequences | according to visual analysis of artifacts and number of negative voxels | Baseline | |
Secondary | Inter-observer agreement of the interpretation of the perfusion data | Intra Class correlation coefficient | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04364932 -
Antenatal and Intrapartum Risk Factors Associated With Neonatal Hypoxic Ischemic Encephalopathy
|
||
Not yet recruiting |
NCT05648812 -
Neonatal Brain Ultrasound With CEUS and Elastography
|
Phase 3 | |
Completed |
NCT00593242 -
Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy
|
Phase 1 | |
Not yet recruiting |
NCT03550612 -
Neonatal Hypoxic Ischemic Encephalopathy:Early Diagnosis and Management of Comorbidities
|